Actinium Pharmaceuticals, Inc. (ATNM)
AMEX$1.21
Market Cap
$37.75M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
467 of 924
Rank in Industry
276 of 527
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
ATNM Insider Trading Activity
ATNM Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
Related Transactions
No records found
About Actinium Pharmaceuticals, Inc.
Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center. The company also offers …
Insider Activity of Actinium Pharmaceuticals, Inc.
Over the last 12 months, insiders at Actinium Pharmaceuticals, Inc. have bought $0 and sold $0 worth of Actinium Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Actinium Pharmaceuticals, Inc. have bought $0 and sold $0 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 10,000 shares for transaction amount of $4,372 was made by SETH SANDESH (Chairman & CEO) on 2018‑12‑10.
List of Insider Buy and Sell Transactions, Actinium Pharmaceuticals, Inc.
| 2018-12-10 | SETH SANDESH | Chairman & CEO | 10,000 0.0095% | $0.44 | $4,372 | -37.73% | ||
| 2018-12-10 | O'Loughlin Steve | Principal Financial Officer | 10,000 0.0095% | $0.43 | $4,350 | -37.73% | ||
| 2018-11-19 | Ludwig Dale L. | Chief Scientific Officer | 10,000 0.01% | $0.45 | $4,499 | -31.63% | ||
| 2018-07-17 | SETH SANDESH | CEO | 10,000 0.0094% | $0.79 | $7,900 | -28.76% | ||
| 2018-06-15 | O'Loughlin Steve | Principal Financial Officer | 12,000 0.0109% | $0.50 | $6,000 | +14.08% | ||
| 2018-04-19 | SETH SANDESH | Chairman & CEO | 5,000 0.0045% | $0.38 | $1,900 | +50.20% | ||
| 2018-02-28 | Shetty Ajit | director | 22,730 0.0257% | $0.43 | $9,774 | +25.81% | ||
| 2017-08-02 | SETH SANDESH | Chairman & CEO | 33,333 0.0538% | $0.75 | $25,000 | -3.30% | ||
| 2017-08-02 | Ray Nitya G. | Executive Vice President | 10,000 0.0161% | $0.75 | $7,500 | -3.30% | ||
| 2017-06-15 | SETH SANDESH | Chairman and CEO | 7,500 0.013% | $1.16 | $8,725 | -45.53% | ||
| 2017-06-15 | Berger Mark Stanley | Chief Medical Officer | 5,000 0.0083% | $1.11 | $5,550 | -45.53% | ||
| 2017-06-15 | O'Loughlin Steve | Principal Financial Officer | 3,500 0.0061% | $1.17 | $4,095 | -45.53% | ||
| 2016-12-30 | SETH SANDESH | Executive Chairman | 5,000 0.0104% | $0.88 | $4,400 | +16.57% | ||
| 2016-12-12 | SETH SANDESH | Executive Chairman | 5,000 0.0104% | $0.98 | $4,900 | +5.15% | ||
| 2016-08-31 | Sale | Memorial Sloan-Kettering Cancer Center | 10 percent owner | 136,853 0.2928% | $1.83 | $251,118 | -34.31% | |
| 2016-08-30 | Sale | Memorial Sloan-Kettering Cancer Center | 10 percent owner | 56,074 0.1174% | $1.81 | $101,254 | -33.90% | |
| 2016-08-29 | Sale | Memorial Sloan-Kettering Cancer Center | 10 percent owner | 25,000 0.0529% | $1.72 | $42,875 | -28.89% | |
| 2016-08-26 | Sale | Memorial Sloan-Kettering Cancer Center | 10 percent owner | 25,000 0.052% | $1.70 | $42,620 | -29.07% | |
| 2016-08-16 | Sale | Memorial Sloan-Kettering Cancer Center | 10 percent owner | 5,029 0.0107% | $1.72 | $8,652 | -26.18% | |
| 2016-08-15 | Sale | Memorial Sloan-Kettering Cancer Center | 10 percent owner | 4,439 0.0093% | $1.72 | $7,635 | -25.87% |
Total: 48
Insider Historical Profitability
<0.0001%
| SETH SANDESH | Chairman & CEO | 153333 0.4915% | $185,532.93 | 10 | 0 | <0.0001% |
| DAVE KAUSHIK J | CEO and Interim CFO | 88500 0.2837% | $107,085.00 | 1 | 0 | <0.0001% |
| O'Loughlin Steve | Principal Financial Officer | 35500 0.1138% | $42,955.00 | 3 | 0 | <0.0001% |
| Shetty Ajit | director | 22730 0.0729% | $27,503.30 | 1 | 0 | +25.81% |
| Nicholson, C. David | director | 15000 0.0481% | $18,150.00 | 1 | 0 | <0.0001% |
Historical Insider Profitability vs. Competitors
$22,186,116 | 57 | -43.73% | $35.88M | |
$140,938,207 | 36 | 14.75% | $40.58M | |
$23,895,365 | 34 | -37.28% | $35.88M | |
Actinium Pharmaceuticals, Inc. (ATNM) | $241,165 | 22 | -16.72% | $37.75M |
$167,476,357 | 20 | -1.54% | $40.57M |
ATNM Institutional Investors: Active Positions
| Increased Positions | 41 | +51.9% | 980,865 | +11.59% |
| Decreased Positions | 32 | -40.51% | 1M | -15.62% |
| New Positions | 14 | New | 172,649 | New |
| Sold Out Positions | 19 | Sold Out | 776,489 | Sold Out |
| Total Postitions | 88 | +11.39% | 8M | -4.03% |
ATNM Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Blackrock, Inc. | $2,426.00 | 6.36% | 1.97M | +33,483 | +1.73% | 2024-12-31 |
| Vanguard Group Inc | $1,989.00 | 5.22% | 1.62M | -7,628 | -0.47% | 2024-12-31 |
| Geode Capital Management, Llc | $846.00 | 2.22% | 687,853 | +1,700 | +0.25% | 2024-12-31 |
| State Street Corp | $764.00 | 2% | 621,075 | +18,426 | +3.06% | 2024-12-31 |
| Acadian Asset Management Llc | $614.00 | 1.61% | 499,260 | +45,566 | +10.04% | 2024-12-31 |
| Northern Trust Corp | $310.00 | 0.81% | 251,930 | +11,812 | +4.92% | 2024-12-31 |
| Morgan Stanley | $266.00 | 0.7% | 216,134 | +102,443 | +90.11% | 2024-12-31 |
| Los Angeles Capital Management Llc | $263.00 | 0.69% | 213,950 | +42,770 | +24.98% | 2024-12-31 |
| Renaissance Technologies Llc | $234.00 | 0.61% | 190,400 | +63,400 | +49.92% | 2024-12-31 |
| Squarepoint Ops Llc | $225.00 | 0.59% | 183,262 | +37,159 | +25.43% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.